Ubs Group Ag Adagene Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ADAG
# of Institutions
13Shares Held
9.87MCall Options Held
0Put Options Held
0-
Wu Xi App Tec Co., Ltd. Shanghai, F43.98MShares$8.8 Million46.44% of portfolio
-
Fil LTD Hamilton, D03.6MShares$7.96 Million0.01% of portfolio
-
Sc China Holding LTD N/A, K31.34MShares$2.97 Million0.11% of portfolio
-
General Atlantic LLC New York, NY264KShares$583,4400.02% of portfolio
-
Exome Asset Management LLC New York, NY263KShares$580,4010.4% of portfolio
About Adagene Inc.
- Ticker ADAG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,423,200
- Market Cap $96M
- Description
- Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...